EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A New Multigram Synthetic Process to Cabotegravir

Xiaoyi Li, Chao Yan, Bo Jin, Rui Zhang, Boyang Wu, Jiachen Wen, Yan Zhao, Lin-xiang Zhao

Synlett · 2026-11 · 37 (18) · 1749-1754

DOI: 10.1055/a-2919-0987 ↗
AbstractBibliografische Angaben

Abstract

Abstract Cabotegravir, a long-acting integrase strand transfer inhibitor, is clinically used for HIV treatment and prevention. Current synthetic processes for cabotegravir are limited to either low scalability or prolonged reaction times. In response to the demand for a scalable synthesis method, we report a novel synthetic route enabling multigram-scale production of cabotegravir. Starting from commercially available 1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid, we have developed a five-step synthetic route that offers improved synthetic efficiency compared to the literature method. Key improvements include the following: (1) a two-step deacetalization-cyclization avoids the strongly acidic conditions and raises the combined yield from 74% to 96%, (2) a one-pot esterification–transamidation eliminating moisture-sensitive reagents and imidazole byproduct, and (3) replacement of the final demethylation and recrystallization conditions, improving safety and purity (99.91%). The overall yield has increased from 65% to 72%, and the total reaction period has reduced from 52 to 31 h. The process is robust, reproducible, and well suited for laboratory-scale production.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →